Kodiak Sciences (KOD) Stock Price, News & Analysis

Company Overview

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for retinal diseases. Headquartered in Palo Alto, California, Kodiak leverages proprietary antibody biopolymer conjugate (ABC) technology to create targeted treatments that aim to improve durability, durability and efficacy in the eye. The company was founded in 2009 and has steadily advanced a pipeline of product candidates designed to address unmet needs in chronic ophthalmic conditions.

The company’s lead candidate, KSI-301, is an anti-VEGF antibody biopolymer conjugate that is being evaluated in pivotal Phase 3 studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). By combining a high-molecular-weight polymer with an anti-VEGF antibody, KSI-301 is engineered to extend treatment intervals and potentially reduce the frequency of intravitreal injections for patients. Kodiak has also initiated early-stage programs exploring novel targets in retinal vascular disease and inherited retinal disorders.

Kodiak Sciences operates research and development facilities in both the United States and Europe, enabling global collaboration and clinical trial execution across multiple geographies. The company has established strategic partnerships with academic institutions and contract research organizations to support its translational efforts. Kodiak’s international reach is further strengthened by regulatory interactions in key markets, positioning the company to seek approvals and commercial launches in North America, Europe and select Asia-Pacific territories.

Leadership at Kodiak Sciences includes President and Chief Executive Officer Victor Perlroth, who brings extensive experience in ophthalmology drug development, and Chief Medical Officer Manjula Mahajan, M.D., a recognized expert in retinal disease clinical research. The management team and board combine scientific, clinical and commercial expertise to drive the advancement of Kodiak’s pipeline. As Kodiak continues its late-stage programs, the company remains committed to delivering transformative therapies for patients suffering from vision-threatening conditions.

Key Stats

• Today's Range: $3.85 to $4.01
• 50-Day Range: $3.33 to $4.92
• 52-Week Range: $1.92 to $11.60
• Volume: 311,539 shs
• Average Volume: 346,421 shs
• Market Capitalization: $208.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Kodiak Sciences Stock Analysis - MarketRank™

Kodiak Sciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 175th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Kodiak Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kodiak Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.45) to ($3.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kodiak Sciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kodiak Sciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kodiak Sciences has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.19% of the float of Kodiak Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kodiak Sciences has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Kodiak Sciences has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kodiak Sciences does not currently pay a dividend.

Dividend Growth

Kodiak Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

4.19% of the float of Kodiak Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kodiak Sciences has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Kodiak Sciences has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for KOD on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kodiak Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.90% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KOD Stock Analysis - Frequently Asked Questions

How have KOD shares performed this year?

Kodiak Sciences' stock was trading at $9.95 on January 1st, 2025. Since then, KOD stock has decreased by 60.2% and is now trading at $3.96.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) posted its earnings results on Wednesday, May, 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.20.

When did Kodiak Sciences IPO?

Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

How do I buy shares of Kodiak Sciences?

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KOD
• CIK: 1468748
• Web: kodiak.com
• Phone: (650) 281-0850
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +127.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$176.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.71%
• Return on Assets: -54.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 4.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.86 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 52,760,000
• Free Float: 28,545,000
• Market Cap: $208.93 million
• Optionable: Optionable
• Beta: 2.28